Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1962 2
1981 1
1982 2
1985 1
1987 1
1989 1
1991 1
1993 1
1994 1
1997 1
1998 1
1999 3
2002 2
2003 2
2004 3
2008 1
2009 1
2010 1
2011 1
2012 1
2013 1
2014 1
2016 1
2017 2
2018 1
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Carbetimer: a re-evaluation of a drug with a novel mechanism of action.
Ardalan B, Hussein AM, Shanahan WR Jr, Shields MJ. Ardalan B, et al. Among authors: shanahan wr jr. Cancer Treat Rev. 1991 Mar;18(1):73-83. doi: 10.1016/0305-7372(91)90005-k. Cancer Treat Rev. 1991. PMID: 1933912 Free article. Review. No abstract available.
Making sense of antisense.
Yacyshyn BR, Shanahan WR Jr. Yacyshyn BR, et al. Among authors: shanahan wr jr. Can J Gastroenterol. 1999 Nov;13(9):745-51. doi: 10.1155/1999/154140. Can J Gastroenterol. 1999. PMID: 10633827 Review.
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Smith SR, et al. Among authors: shanahan wr. N Engl J Med. 2010 Jul 15;363(3):245-56. doi: 10.1056/NEJMoa0909809. N Engl J Med. 2010. PMID: 20647200 Free article. Clinical Trial.
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Merrill JT, et al. Among authors: shanahan wr. Ann Rheum Dis. 2018 Jun;77(6):883-889. doi: 10.1136/annrheumdis-2018-213032. Epub 2018 Mar 21. Ann Rheum Dis. 2018. PMID: 29563108 Clinical Trial.
35 results